Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 [mavrilimumab] in Patients With Rheumatoid Arthritis.

Next Previous
X
Search
Trial Profile

A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 [mavrilimumab] in Patients With Rheumatoid Arthritis.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavrilimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors MedImmune

    • Most Recent Events

    • 02 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 02 Nov 2011 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
    • 25 May 2011 Results published in the Annals of the Rheumatic Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top